Results 61 to 70 of about 1,702,455 (203)

Thrombocytopenia in Pregnancy: A 5‐Year Analysis of Characteristics and Practices From a Tertiary Academic Center

International Journal of Laboratory Hematology, Volume 48, Issue 6, Page 1320-1329, December 2026.
ABSTRACT Background Moderate‐to‐severe thrombocytopenia (platelet count < 100 × 109/L) occurs in fewer than 1% of pregnancies, posing management challenges, particularly surrounding eligibility for neuraxial anesthesia. Although recent anesthesia guidelines recommend a platelet threshold ≥ 70 × 109/L, outcomes data applying these recommendations in ...
Mackenzie E. Lemieux, Ming Y. Lim
wiley   +1 more source

Bispecific antibodies targeting B‐cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions

Cancer, Volume 132, Issue 22, 15 November 2026.
Abstract Anti‐B cell maturation antigen (BCMA) therapies, including antibody‐drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma. This review outlines the biologic rationale for targeting BCMA and sheds light on the mechanism of action of bsAbs ...
Enrica Manzato, Gloria Cocchetto, Simona Barbato, Michele Puppi, Simone Masci, Elena Zamagni   +5 more
wiley   +1 more source

Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

American Journal of Hematology, Volume 101, Issue 11, Page 2836-2852, November 2026.
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas, Nichola Cooper, Vickie McDonald, Karina Yazdanbakhsh, Wilma Barcellini   +4 more
wiley   +1 more source

PP025 Thrombopoietin Receptor Agonist For Treatment Of Adults With Chronic Immune Thrombocytopenic Purpura

, 2017
INTRODUCTION:This study aims to report the clinical effectiveness and cost-effectiveness of Thrombopoietin (TPO) receptor agonist for the treatment of adults with spontaneous Immune Thrombocytopenic Purpura (ITP) in Taiwan.METHODS:In the clinical ...
Gau Churn-Shiouh, Huang Grace Li Ying
core   +1 more source

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia [PDF]

, 2012
Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are ...
Andriulli, A, Giannini, Edoardo G, Russo M, Pinzello G, Iaquinto G, Prieto Castillo M, Savarino V, Gambarin Gelwan M, Chen PJ, Abrams C, Afdhal, Nezam H, ELEVATE Study Group [..., Andreone P, Bzowej N, Caro Patón A, Terg R, Fallon M, Giannini EG, Mohsin, A, Navasa Anadón M, Chuang WL, Fontana R, Bilodeau M, Tayyab, Ghias, Colombo M, Homenda W, Botta Fridlund D, Rizzetto M, Moreno C, Satyanaryana R, Kim K, McHutchison, John G, Xiol Quingles X, Gugenheim J, Riley T, Hyde, Denise, Fontanella A, Afdhal, NH, Vargas H, Campbell, F, Te H, Brainsky, Andres, Mohsin A, Rapaccini G, Graus Morales J, Sterling R, Sigal S, Solá Lamoglia R, Colombato L, Mazur W, Di Leo A, MAZZELLA, GIUSEPPE, Gish R, Lee JW, Finazzi R, Hyde, D, Giannini, EG, Lee W, Samuel D, Grieco, Antonio, CRAXI, Antonio, Carbonell N, Tayyab G, Francavilla A, Brainsky A, Kwo P, Elkasahab M, Lee, Jin-Woo, Han KH, Dumortier J, Grieco A, Sánchez Antolín G, Campbell, Fiona, Kang H, Everson G, Nijhawan S, Han, Kwang-Hyub, Lee JH, Kuliczkowski K, Lee YS, Hyde D, Muñoz A, Diago M, Morozov V, Botta-Fridlund D, Chen, Pei-Jer, Bessonova E, Chen, PJ, Han, KH, Zaman A, Thuluvath P, Moreno, Christophe, Rewak W, Rodrigo Lopez J, Jeffers L, ...], Trepo C, Akram J, Theodore, D, ANDREONE, PIETRO, Gadano A, Khan Z, Andriulli, Angelo, McHutchison, J, Afdhal, Nezam, Fedeli G, Jeffers, L, Rafalsky V, Mohsin, Aftab, Tayyab, G, Brainsky, A, McHutchison J, Craxi A, Shiffman M, Cardenas A, Afdhal NH, Gambarin-Gelwan M, Jeffers, Lennox, Theodore D, Cholewinska G, Bloomer J, Theodore, Dickens, Ripoll Noiseux C, Campbell F, Andriulli A, Tanno H, Lee, JW, Calmus Y, Gordon F, Poordad F, Regenstein F, McHutchison, John, Mazzella G   +132 more
core   +1 more source

Avatrombopag in heavily pretreated chronic immune thrombocytopenia: a single center experience from Oman

Frontiers in Medicine
BackgroundChronic immune thrombocytopenia (ITP) is characterized by persistent thrombocytopenia and bleeding risk, and a subset of patients remains refractory or relapses despite multiple lines of therapy.
Nashwa Al-Sharji, Bushra Salman, Shireen Al-Zadjali, Mohammed Al-Huneini   +3 more
doaj   +1 more source

Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trial

Cancer, Volume 132, Issue 21, 1 November 2026.
Abstract Background Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.
Arnaud Pigneux, Pierre‐Yves Dumas, Marc Bernard, Norbert Vey, Audrey Bidet, Ariane Mineur, Aline Schmidt, Martin Carré, Mario Ojeda, Sarah Bertoli, Anne Banos, Pierre Peterlin, Romain Guièze, Yohan Desbrosses, Gabrielle Roth Guepin, Célestine Simand, Thibaut Leguay, Emmanuel Gyan, Eric Jourdan, Jean‐Philippe Vial, Tony Marchand, Yosr Hicheri, Marie C. Béné, Jean Francois Hamel, Christian Récher   +24 more
wiley   +1 more source

Successful avatrombopag combined with cyclosporine treatment for carboplatin/pegylated liposomal doxorubicin/bevacizumab-induced acquired amegakaryocytic thrombocytopenia in a patient with recurrent ovarian cancer: case report

Frontiers in Oncology
Carboplatin/pegylated liposomal doxorubicin/bevacizumab is an accepted standard anti-cancer treatment option for recurrent ovarian cancer. However, the occurrence of adverse events associated with this therapeutic regimen limits its continued clinical ...
Weikang Meng, Jinsheng Hua, Jiabing Wang
doaj   +1 more source

Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC

HemaSphere, Volume 10, Issue 11, November 2026.
Abstract The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based ...
Candida Vitale, Thomas Chatzikonstantinou, Christina Papangelou, Francesca Perutelli, Maria Chiara Montalbano, Giulia Bondielli, Elia Boccellato, Salem Alshemmari, Francesco Angotzi, Miguel Arguello‐Tomas, Tomas Arpas, Sandra Bašić‐Kinda, Sotiria Besikli‐Dimou, Łukasz Bołkun, Tomasz Buczek, Aleksandra Butrym, Katherine Chapis, Sofia Chatzileontiadou, Rosa Collado, Raul Cordoba Mascuñano, Lorenzo De Paoli, Marina Deodato, Maria Dimou, David Donaldson, Joanna Drozd‐Sokołowska, Salem Elias, Andrea Ferrario, Alberto Fresa, Anna Maria Frustaci, Rocío García‐Serra, Ajay Gogia, Isabel González‐Gascón‐y‐Marín, Vasko Graklanov, Maria Hryniewiecka, Zhu Huayuan, Elzbieta Iskierka‐Jażdżewska, Paula Jablonowska‐Babij, Ozren Jaksic, Elzbieta Kalicińska, Maria Kislova, Maya Koren‐Michowitz, Epameinondas Koumpis, Zuzana Kubová, Jorge Labrador, Pietro Lauzzana, Shai Levi, Francesca Martini, Mariia Mikhaleva, Eva Minga, Riccardo Moia, Elżbieta Morawiec‐Szymonik, Marta Morawska, Femke V. M. Mulder, Roberta Murru, Jacopo Olivieri, Ewa Paszkiewicz‐Kozik, Lata Rani, Josep Maria Roncero, Wojciech Salamon, Alessandro Sanna, Lydia Scarfò, Tereza Shokralla, Martin Šimkovič, Matevž Škerget, Emil Spasov, Antigoni Tranidou, Jagoda Tryc‐Szponder, Marzia Varettoni, Andrea Visentin, George Vrachiolias, David Waddell, Ewa Wasik‐Szczepanek, Kamil Wdowiak, Mateusz Wilk, Kamil Wiśniewski, Magdalena Witkowska, Mohamed Yassin, Seyma Yıldız, Klaudia Zielonka, Nil Albiol, Jennifer R. Brown, Benedetto Bruno, Mark Catherwood, Anastasia Chatzidimitriou, Michael Doubek, Gianluca Gaidano, Alessandro Gozzetti, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Krzysztof Jamroziak, Ioannis Kotsianidis, Luca Laurenti, Eugene Nikitin, Maria Papaioannou, Tomáš Papajik, Martin Špaček, Niki Stavroyianni, Josephine M. I. Vos, Tomasz Wróbel, Münci Yağcı, Arnon P. Kater, Matthew Davids, Petra Langerbeins, Kostas Stamatopoulos, Paolo Ghia, Marta Coscia   +106 more
wiley   +1 more source

Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study

BMC Gastroenterology, 2020
Background Chronic liver disease (CLD) is often complicated by severe thrombocytopenia (platelet count  50,000/µL at baseline: the proportions of patients who did not require platelet transfusion were 84–96%, which might be overestimated.
Hiroaki Nomoto, Naoki Morimoto, Kouichi Miura, Shunji Watanabe, Yoshinari Takaoka, Hiroshi Maeda, Takahiro Sasaki, Yohei Koyashiki, Hidekazu Kurata, Norikatsu Numao, Norio Isoda, Hironori Yamamoto   +11 more
doaj   +1 more source